Home
About
Team
JOT Founders and Leadership Team
>
Christer Rosén
Jacob Uittenbogaard
Dr. Claes Wahlestedt, MD, Ph.D.
Marshall Hayward, Ph.D.
Shaun P Brothers, Ph.D.
Natalie McNamee
Alison Silva
Advisors
>
Scientific Advisory Board
Business Advisors
Sports Ambassadors
JOT101 Project Advisors
JOTROL™
JOTROL™ Pre-Clinical Studies
Pipeline
Friedreich's Ataxia (JOT101)
MELAS Syndrome (JOT107)
Alzheimer's Disease (JOT108)
MPS III (JOT109)
Partners
News
Contact
Investors
Menu
Home
About
Team
JOT Founders and Leadership Team
>
Christer Rosén
Jacob Uittenbogaard
Dr. Claes Wahlestedt, MD, Ph.D.
Marshall Hayward, Ph.D.
Shaun P Brothers, Ph.D.
Natalie McNamee
Alison Silva
Advisors
>
Scientific Advisory Board
Business Advisors
Sports Ambassadors
JOT101 Project Advisors
JOTROL™
JOTROL™ Pre-Clinical Studies
Pipeline
Friedreich's Ataxia (JOT101)
MELAS Syndrome (JOT107)
Alzheimer's Disease (JOT108)
MPS III (JOT109)
Partners
News
Contact
Investors
Developing Therapies for Alzheimer’s Disease as well as Targeted Rare Diseases Through Our Platform Product,
JOT
ROL
™
Home
About
Team
JOT Founders and Leadership Team
>
Christer Rosén
Jacob Uittenbogaard
Dr. Claes Wahlestedt, MD, Ph.D.
Marshall Hayward, Ph.D.
Shaun P Brothers, Ph.D.
Natalie McNamee
Alison Silva
Advisors
>
Scientific Advisory Board
Business Advisors
Sports Ambassadors
JOT101 Project Advisors
JOTROL™
JOTROL™ Pre-Clinical Studies
Pipeline
Friedreich's Ataxia (JOT101)
MELAS Syndrome (JOT107)
Alzheimer's Disease (JOT108)
MPS III (JOT109)
Partners
News
Contact
Investors
